Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 6:59:101741.
doi: 10.1016/j.ijcha.2025.101741. eCollection 2025 Aug.

Impact of diabetes on three-year outcome after coronary stenting in patients with polyvascular atherosclerotic disease - a secondary analysis of the randomized TWENTE trials

Daphne van Vliet  1   2 , Tineke H Pinxterhuis  1   2 , Eline H Ploumen  1   2 , Marlies M Kok  1 , Rosaly A Buiten  1 , Paolo Zocca  1 , Ariel Roguin  3 , Carl E Schotborgh  4 , Rutger L Anthonio  5 , Peter W Danse  6 , Edouard Benit  7 , Adel Aminian  8   9 , Carine J M Doggen  2 , Clemens von Birgelen  1   2
Affiliations

Impact of diabetes on three-year outcome after coronary stenting in patients with polyvascular atherosclerotic disease - a secondary analysis of the randomized TWENTE trials

Daphne van Vliet et al. Int J Cardiol Heart Vasc. .

Abstract

Background: The presence of polyvascular atherosclerotic disease is associated with a high-risk of adverse events following percutaneous coronary intervention (PCI). As the extent to which the presence of diabetes further increases this elevated risk is unclear, based on current literature, we sought to assess the long-term outcome after PCI in patients with polyvascular disease, comparing those with and without diabetes.

Methods: The current study population consists of patients with known polyvascular disease, identified from a pooled patient-level database of 4 PCI trials in all-comers treated with new-generation drug-eluting stents; no exclusion criteria were set. The main composite endpoint was major adverse cardiac event (MACE: any myocardial infarction, emergent coronary bypass surgery, clinically indicated target lesion revascularization, or all-cause mortality).

Results: 695 patients had polyvascular disease of whom 208(29.9 %) had diabetes. Patients with diabetes were older, had a higher body-mass-index, and had a higher prevalence of hypertension than those without diabetes. At 3-year follow-up, the incidence of MACE was significantly higher in polyvascular disease patients with diabetes (24.6 % vs.16.4 %, adj.HR:1.49, 95 %CI:1.05-2.12, p = 0.03), in particular insulin-treated patients, and was primarily attributable to a disparity in all-cause mortality which was more than twice as high in patients with diabetes (15.4 % vs.7.2 %, p < 0.001). Furthermore, the risk of repeated target vessel revascularization was higher in patients with diabetes (12.0 % vs7.0 %, adj.HR:1.88, 95 %CI:1.12-3.16, p = 0.02).

Conclusions: In the high-risk population of PCI patients with polyvascular disease, the presence of diabetes represents a profoundly significant additional risk factor at long-term follow-up, associated with significantly higher adverse event risks.Trial registration:ClinicalTrials.gov NCT01066650 NCT0133170 NCT01674803 NCT02508714.

Keywords: Coronary artery disease; Diabetes mellitus; Percutaneous coronary intervention; Peripheral arterial disease; Polyvascular disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Graphical abstract.
Fig. 2
Fig. 2
Study flowchart.
Fig. 3
Fig. 3
Kaplan-Meier time-to-event curves of the incidence of major adverse cardiac events and individual components: Major adverse cardiac events (A), any myocardial infarction (B), target lesion revascularization (C), and all-cause mortality (D). Abbreviations: PADs = peripheral arterial disease, HR = hazard ratio, CI = confidence interval.
See this image and copyright information in PMC

References

    1. Vidakovic R., Schouten O., Kuiper R., et al. The prevalence of polyvascular disease in patients referred for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38:435–440. doi: 10.1016/j.ejvs.2009.05.006. - DOI - PubMed
    1. Morikami Y., Natsuaki M., Morimoto T., et al. Impact of polyvascular disease on clinical outcomes in patients undergoing coronary revascularization: an observation from the CREDO-Kyoto Registry Cohort-2. Atherosclerosis. 2013;2(228):426–431. doi: 10.1016/j.atherosclerosis.2013.04.005. - DOI - PubMed
    1. Gutierrez J.A., Aday A.W., Patel M.R., Jones W.S. Polyvascular disease: reappraisal of the current clinical landscape. Circ Cardiovasc Interv. 2019;12(12) - PMC - PubMed
    1. Suárez C., Zeymer U., Limbourg T., et al. REACH Registry investigators. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med. 2010;15(4):259–265. doi: 10.1177/1358863X10373299. - DOI - PubMed
    1. Kobo O., Saada M., von Birgelen C., et al. Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry. Eur Heart J Qual Care Clin Outcomes. 2023 Jun 21;9(4):417–426. - PMC - PubMed

Associated data